Mechanisms of TL1A-driven Paneth Cell dysfunction in IBD

IBD 中 TL1A 驱动的潘氏细胞功能障碍的机制

基本信息

  • 批准号:
    10077845
  • 负责人:
  • 金额:
    $ 38.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-01-01 至 2023-12-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY ABSTRACT Inflammatory bowel diseases (IBD) are chronic relapsing diseases of the gastrointestinal tract believed to be the result of complex interactions between genetic susceptibility and severity genes, the microbial environment, and a dysregulated innate and adaptive immune response against commensal micro-organisms. Paneth cells (PC) are specialized small bowel (SB) epithelial cells that constitutively produce anti-microbial proteins and are important in intestinal homeostasis. Abnormal PC morphology is observed in patients with Crohn’s disease (CD) and in mice with gene deletions in autophagy and unfolded protein response (UPR) pathways. Mice with PC-specific deletions in UPR and autophagy pathways develop early and severe SB inflammation. PC morphologic abnormalities precede onset of ileitis, implicating altered PC biology as central to the pathogenesis and severity of SB CD; yet the cell-extrinsic signals driving these abnormalities are undefined. TNFSF15/(TL1A) is an IBD susceptibility and severity locus and we have previously reported the relationship of a TNFSF15 risk genotype and increased expression of TL1A in peripheral monocytes and in non- inflamed SB CD. In translational studies, we also reported the association between this risk genotype and severe forms of SB CD including fibrostenosis that was phenocopied in mice overexpressing TL1A. We have found a significant association between TL1A and abnormal PC morphology. Commensal microbiota are required in TL1A-overexpressing mice to induce ileal inflammation and in wild type mice to induce normal PC maturation and expansion. We developed a novel stem cell micro-engineered chip model of functional human PC, we showed TL1A directly alters the PC phenotype by inducing diffused and disordered lysozyme granule morphology recapitulating the abnormal PC phenotypes in SB CD with high mucosal expression of TL1A. Evidence that serum levels of IBD-associated anti-bacterial antibodies are elevated in unaffected family members of patients with IBD and also in members of the military prior to clinical evidence of disease suggests defects in the host-bacterial interface precedes onset of IBD. Loss of response to biologics and disease recurrence may represent elimination of a disease driving cytokine but not the underlying process. If pre- inflammatory PC abnormality can be mitigated/prevented by manipulation of TL1A, which, addresses the microbial-host interface, potentially PC function will reset and IBD may be pre-empted in genetically susceptible individuals, and the combination may also prevent loss of response to existing therapeutics or disease recurrence. The foregoing provides a strong rationale for studying the mechanisms of TL1A-driven changes in PC morphology, maturation, and function in promoting SB inflammation, using our novel murine in vivo and human stem cell in vitro systems that allow for parallel investigations to parse out cellular and molecular interactions simultaneously. Our investigations will reveal additional downstream pathways and molecules and potentially targets for combination therapy.
项目摘要 炎症性肠病(IBD)是胃肠道的慢性复发性疾病,被认为是 遗传易感性和严重性基因,微生物环境, 以及针对肠道微生物的先天性和适应性免疫应答失调。潘氏细胞 (PC)是特化的小肠(SB)上皮细胞,其组成性地产生抗微生物蛋白, 对肠道内环境稳定很重要。克罗恩病患者PC形态异常 (CD)以及自噬和未折叠蛋白反应(UPR)途径基因缺失的小鼠。小鼠 UPR和自噬途径中的PC特异性缺失会导致早期和严重的SB炎症。PC 形态学异常先于回肠炎发作,暗示PC生物学改变是回肠炎的核心。 SB CD的发病机制和严重程度;但驱动这些异常的细胞外在信号尚不明确。 TNFSF 15/(TL 1A)是IBD易感性和严重程度的基因座,我们之前已经报道了这种关系 TNFSF 15风险基因型和TL 1A在外周血单核细胞和非单核细胞中的表达增加。 SB CD发炎。在翻译研究中,我们也报道了这种风险基因型与 严重形式的SB CD,包括在过表达TL 1A的小鼠中表现出的纤维狭窄。我们有 发现TL 1A和异常PC形态之间存在显著关联。共生菌群 在TL 1A过表达小鼠中诱导回肠炎症和在野生型小鼠中诱导正常PC 成熟和扩张。我们开发了一种新的干细胞微工程芯片模型, 结果表明,TL 1A通过诱导溶菌酶颗粒的分散和无序,直接改变PC的表型 形态学重现了具有TL 1A高粘膜表达的SB CD中的异常PC表型。 IBD相关抗细菌抗体的血清水平在未受影响的家族中升高的证据 IBD患者的成员以及军队成员在疾病的临床证据表明, 宿主-细菌界面的缺陷先于IBD发作。对生物制剂和疾病失去反应 复发可能代表疾病驱动细胞因子的消除,而不是潜在过程。如果预- 炎症性PC异常可以通过TL 1A的操作来减轻/预防,TL 1A解决了 微生物-主机接口,PC功能可能会重置,并且IBD可能会在基因上被抢占 该组合还可以防止对现有治疗剂的反应丧失, 疾病复发。上述内容为研究TL 1A驱动的细胞凋亡的机制提供了强有力的理论基础。 PC形态、成熟和促进SB炎症的功能的变化,使用我们的新的小鼠模型, 体内和人干细胞体外系统,允许并行研究,以解析出细胞和 分子间的相互作用。我们的研究将揭示更多的下游途径, 分子和联合治疗的潜在靶点。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Stephan R. Targan其他文献

Serial 6-mercaptopurine (6-MP) metabolite measurements in combination with dose escalation unmasks an important biochemical explanation for "6-MP resistance"
  • DOI:
    10.1016/s0016-5085(00)85698-x
  • 发表时间:
    2000-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Marla C. Dubinsky;Philip V. Hassard;Lori Y. Kam;Maria T. Abreu;Ernest G. Seidman;Stephan R. Targan;Eric A. Vasiliauskas
  • 通讯作者:
    Eric A. Vasiliauskas
Thioguanine (6-TG): A therapeutic alternative in a subgroup of IBD patients failing 6-mercaptopurine (6-MP)
  • DOI:
    10.1016/s0016-5085(00)85701-7
  • 发表时间:
    2000-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Marla C. Dubinsky;Philip V. Hassard;Maria T. Abreu;Lori Y. Kam;Ernest G. Seidman;Stephan R. Targan;Eric A. Vasiliauskas
  • 通讯作者:
    Eric A. Vasiliauskas
704 – Preoperative Serum Vedolizumab Levels Do Not Impact Postoperative Outcomes in Inflammatory Bowel Disease
  • DOI:
    10.1016/s0016-5085(19)37178-1
  • 发表时间:
    2019-05-01
  • 期刊:
  • 影响因子:
  • 作者:
    Aaron B. Parrish;Karen Zaghiyan;Nicole Lopez;Gil Melmed;Dermot McGovern;Anjali Jain;Carol Landers;Stephan R. Targan;Phillip Fleshner
  • 通讯作者:
    Phillip Fleshner
369: NOVEL ASSOCIATIONS OF SARCOPENIA WITH CLINICAL, RADIOGRAPHIC, BLOOD PARAMETER, AND POLYGENIC RISK SCORE (PRS) MEASURES IN CROHN'S DISEASE (CD)
  • DOI:
    10.1016/s0016-5085(22)60195-1
  • 发表时间:
    2022-05-01
  • 期刊:
  • 影响因子:
  • 作者:
    Shishir Dube;Norman Gellada;Dalin Li;Talin Haritunians;Phillip Gu;Shaohong Yang;Gregory J. Botwin;Stephan R. Targan;Damini Dey;Yaniv Raphael;Cindy Kallman;Dermot P.B. Mcgovern
  • 通讯作者:
    Dermot P.B. Mcgovern
Sa1879 - UBE2L3, ANCA, ASCA, and CBIR1 are Associated with Mechanisms of non-Response to Anti-TNF in IBD Patients with Adequate Drug Levels
  • DOI:
    10.1016/s0016-5085(17)31514-7
  • 发表时间:
    2017-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Leilei Zhu;Gil Melmed;Xiaofei Yan;Talin Haritunians;David Q. Shih;Eric Vasiliauskas;Andrew Ippoliti;Shervin Rabizadeh;Namita Singh;Stephan R. Targan;Zhenqiu Liu;Dalin Li;Dermot McGovern
  • 通讯作者:
    Dermot McGovern

Stephan R. Targan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Stephan R. Targan', 18)}}的其他基金

Mechanisms of TL1A-driven Paneth Cell dysfunction in IBD
IBD 中 TL1A 驱动的潘氏细胞功能障碍的机制
  • 批准号:
    10539302
  • 财政年份:
    2020
  • 资助金额:
    $ 38.25万
  • 项目类别:
Mechanisms of TL1A-driven Paneth Cell dysfunction in IBD
IBD 中 TL1A 驱动的潘氏细胞功能障碍的机制
  • 批准号:
    10311509
  • 财政年份:
    2020
  • 资助金额:
    $ 38.25万
  • 项目类别:
Molecular characterization of the role of RNASET2 in Severe Crohn's Disease
RNASET2 在严重克罗恩病中作用的分子表征
  • 批准号:
    10021036
  • 财政年份:
    2019
  • 资助金额:
    $ 38.25万
  • 项目类别:
Molecular characterization of the role of RNASET2 in Severe Crohn's Disease
RNASET2 在严重克罗恩病中作用的分子表征
  • 批准号:
    10226172
  • 财政年份:
    2019
  • 资助金额:
    $ 38.25万
  • 项目类别:
Role of TRIF-Dependent TLR Signaling in Intestinal Mucosa
TRIF 依赖性 TLR 信号转导在肠粘膜中的作用
  • 批准号:
    10225616
  • 财政年份:
    2012
  • 资助金额:
    $ 38.25万
  • 项目类别:
IBD: Mucosa Specific Regulation of IFN-gamma Production
IBD:粘膜对 IFN-γ 产生的特异性调节
  • 批准号:
    7921223
  • 财政年份:
    2009
  • 资助金额:
    $ 38.25万
  • 项目类别:
INFLAMMATORY BOWEL DISEASE CENTER: CLINICAL DATA REPOSITORY - TISSUE PROCUREMENT
炎症性肠病中心:临床数据存储库 - 组织采购
  • 批准号:
    8174459
  • 财政年份:
    2009
  • 资助金额:
    $ 38.25万
  • 项目类别:
INFLAMMATORY BOWEL DISEASE CENTER: CLINICAL DATA REPOSITORY - TISSUE PROCUREMENT
炎症性肠病中心:临床数据存储库 - 组织采购
  • 批准号:
    7952200
  • 财政年份:
    2008
  • 资助金额:
    $ 38.25万
  • 项目类别:
CORE--TISSUE PROCUREMENT & DATA ANALYSIS & SERUM ANALYSIS
核心——纸巾采购
  • 批准号:
    7487329
  • 财政年份:
    2007
  • 资助金额:
    $ 38.25万
  • 项目类别:
INFLAMMATORY BOWEL DISEASE CENTER: CLINICAL DATA REPOSITORY - TISSUE PROCUREMENT
炎症性肠病中心:临床数据存储库 - 组织采购
  • 批准号:
    7606129
  • 财政年份:
    2007
  • 资助金额:
    $ 38.25万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 38.25万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.25万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 38.25万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.25万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 38.25万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 38.25万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.25万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 38.25万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 38.25万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.25万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了